Navigation Links
Inverness Medical Innovations Announces Second Quarter 2008 Results
Date:7/29/2008

$0.37 (j)

Weighted average common shares

- basic 77,647 77,647

Weighted average common shares

- diluted 77,647 (i) 82,984 (j)

Three Months Ended June 30, 2007

Non-GAAP

Adjusted

Non-GAAP Cash

GAAP Adjustments Basis (a)

Net revenue $154,965 $- $154,965

Cost of revenue 88,625 (4,545)(b)(d)(e) 84,080

Gross profit 66,340 4,545 70,885

Gross margin 43% 46%

Operating expenses:

Research and development 12,110 (1,161)(b)(d) 10,949

Selling, general and

administrative 95,775 (53,141)(b)(c)(d) 42,634

Total operating expenses 107,885 (54,302) 53,583

Operating income (loss) (41,545) 58,847 17,302

Interest and other income

(expense), net (17,047) 13,458 (b)(f)(g) (3,589)

Income tax (benefit) provision (2,674) 5,931 (h) 3,257

Equity earnings of

unconsolidated entities,

net of tax 1,244 112 (b) 1,356

Net (loss) income $(54,674) $66,486 $11,812

Preferred stock dividends $- $-

Net (loss) income available

to common stockholders -

basic $(54,674) $11,812

Net (loss) income per common

share

Basic
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Inverness - Chemogen Establish Exclusive License for TB Antibodies
3. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
4. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
7. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
8. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
9. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
10. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
11. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... SAN MARINO, Calif., Dec. 15 Epeius ... of targeted genetic medicine, gained international validation of ... Rexin-G , when scientists around the world ... be a major locus of cancer pathogenesis and ... anti-cancer therapies. Recently, scientists at the NIH National ...
(Date:12/15/2009)... 15 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, Inc. ("China ... CSKI ), a,leading fully integrated pharmaceutical company developing ... China ("PRC"), today,announced that the Company has 30 ... of the National Basic Medical Insurance, Industrial Injury ... The 30 medicines treat a variety ...
(Date:12/15/2009)... CHARLOTTESVILLE, Va., Dec. 15 AstraZeneca ... University of Virginia (UVa) in Charlottesville, today ... strategic research collaboration to enhance development of ... (CAD) with a secondary focus on peripheral ... ) ,, The collaborative preclinical research ...
(Date:12/15/2009)... The International Society for Medical Publication ... is continuing to accept abstracts for its 6th ... VA, April 19-21, 2010. This marks the first ... join the organization to submit an abstract to ... 12 AM EST, January 15, 2010. For submission ...
Breaking Biology Technology:Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 2China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 3AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 2The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 3
... Celsis In Vitro Technologies (Celsis,IVT), a division ... and laboratory services company, and Wisconsin-based Promega Corp,will ... testing in primary,hepatocytes. Celsis IVT is pre-qualifying ... Promega,s bioluminescent ADME-Tox assays, including,the P450-Glo(TM) CYP Assay ...
... Clinical and Economic Value of Pharmaceuticals in a ... Pharma today announced the start of the first ... for the Pharmaceutical Industry at the Loews Philadelphia ... marketers with strategic insights needed to prepare for ...
... Sleep Apnea Among Insomnia PatientsALBUQUERQUE, N.M., Feb. 9 ... a grant to study one of the most controversial ... psychological factors -- stress, racing thoughts, and worries -- ... therapy. Pitted against the CW is the provocative ...
Other Biology Technology:Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 2Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 3ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference 2ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference 3Controversial Study to Test Link Between Insomnia and Sleep Apnea 2
(Date:12/16/2009)... inhabited our planet for more than 4 billion years ... by as many eons more. That suggests they may ... Tel Aviv University bacteria expert Prof. Eshel Ben-Jacob of ... Astronomy, grounded in the study of bacteria, presents compelling ... most people should not automatically opt for the swine ...
(Date:12/16/2009)... Maryland School of Medicine researcher will lead the coordinating ... scientists in the field of stem cell research. Michael ... was chosen by the National Heart, Lung and Blood ... of national experts, which will be called the NHLBI ... funded by a $30 million grant over seven years. ...
(Date:12/16/2009)... GestureTek Inc. today announced the ... a turnkey, portable, plug and play interactive ... and touring promotions. GestureTek is the inventor ... camera-enabled gesture recognition technology for interactive display, ... quality, the CUBE has TUV, CE, CSA ...
Breaking Biology News(10 mins):Bacteria wouldn't opt for a swine flu shot 2Bacteria wouldn't opt for a swine flu shot 3University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 3GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 3Elpac Power System Extends Energy Star Portfolio with 65 Watt External Power Supply 54525 1Elpac Power System Extends Energy Star Portfolio with 65 Watt External Power Supply 54525 2Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 1Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 2Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 3Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 4Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 5Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 6Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 7Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 8Oxygen Biotherapeutics Inc to Begin Oxycyte 28R 29 Phase II Clinical Trials in Switzerland 54517 1Oxygen Biotherapeutics Inc to Begin Oxycyte 28R 29 Phase II Clinical Trials in Switzerland 54517 2Oxygen Biotherapeutics Inc to Begin Oxycyte 28R 29 Phase II Clinical Trials in Switzerland 54517 3
... Researchers have discovered the first microRNAs tiny bits ... each of 10 major degenerative muscular disorders, opening doors ... these debilitating, poorly understood, often untreatable diseases. The study, ... of the National Academy of Sciences, was led by ...
... 2007A late-breaking symposium, Colony Collapse Disorder in Honey Bees: ... recently been added to the 55th Annual Meeting of ... in San Diego, December 9-12. The symposium, headed by ... (USDA-ARS), will explore possible factors that may have caused ...
... and University of California-Santa Cruz researcher Hoyt Peckham found ... study that Nichols and Peckham conducted over the course ... on October 17 in the online, open-access journal PLoS ... operations are a greater threat to the survival of ...
Other Biology News:Massive microRNA scan uncovers leads to treating muscle degeneration 2Research shows loggerhead sea turtles threatened by small-scale fishing operations 2
... to siRNA library screening, optimal ... identified and verified for each ... CellReady siRNA Transfection Optimization Kit, ... optimizing transfection conditions in 96 ...
Applications: Western blotting ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid...
Biology Products: